Hypoxia promotes glycogen synthesis and accumulation in human ovarian clear cell carcinoma

International Journal of Oncology

Volumn 40, Issue 6, 2012, Pages 2122-2130

  Iida, Yasushi ^a   Aoki, Katsuhiko ^a   Asakura, Tadashi ^a   Ueda, Kazu ^a   Yanaihara, Nozomu ^a   Takakura, Satoshi ^a   Yamada, Kyosuke ^a   Okamoto, Aikou ^a   Tanaka, Tadao ^a   Ohkawa, Kiyoshi ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Drug resistance; Glycogen storage; HIF1; Ovarian clear cell carcinoma

Indexed keywords

CISPLATIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; DOXORUBICIN; GLUTAMATE CYSTEINE LIGASE; GLYCOGEN; GLYCOGEN SYNTHASE; GLYCOGEN SYNTHASE KINASE 3BETA; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN PHOSPHATASE 1; PROTEIN KINASE B; PROTEIN P110; SERINE; UVOMORULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL HYPOXIA; CELL SURVIVAL; CLEAR CELL CARCINOMA; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; EXON; GENE MUTATION; GENE OVEREXPRESSION; GLYCOGEN ANALYSIS; GLYCOGEN SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; OVARIAN CLEAR CELL CARCINOMA; OVARY CARCINOMA; PERIODIC ACID SCHIFF STAIN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CARCINOMA; CELL HYPOXIA; CELL LINE, TUMOR; CISPLATIN; DNA MUTATIONAL ANALYSIS; DOXORUBICIN; FEMALE; GENE EXPRESSION PROFILING; GLYCOGEN; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 84861790966     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1406     Document Type: Article

References (64)

1. Japanese Gynecologic Cancer Committee: Annual report on Japanese gynecologic cancer committee. Acta Obstet Gynecol Jpn 61, 2009.
2. Mackay HJ, Brady MF, Oza AM, Reuss A, Pujade-Lauraine E, Swart AM, et al: Prognostic relevance uncommon ovarian histology in women with high stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 20: 945-952, 2010.
3. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al: Randamized inter group trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three year results. J Natl Cancer Inst 92: 699-708, 2000. (Pubitemid 30365530)
4. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, et al: Phase III randomized trial of docetaxel-carboplatin versus paclitaxel- carboplatin as first line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96: 1682-1691, 2004. (Pubitemid 39585637)
5. Köbel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, et al: Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Pathol 29: 203-211, 2010.
6. Anglesio MS, Carey MS, Kobel M, Mackay H, Huntsman DG, Vancouver Ovarian Clear Cell Symposium Speakers: Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecol Oncol 121: 407-415, 2011.
7. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, et al: Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88: 2584-2589, 2000. (Pubitemid 30331967)
8. Takano M, Kikuchi Y, Yaegashi N, Kuzuya K, Ueki M, Tsuda H, et al: Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 94: 1369-1374, 2006. (Pubitemid 43772268)
9. Ho CM, Haung YJ, Chen TC, Haung SH, Liu FS, Chang Chien CC, et al: Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol Oncol 94: 197-203, 2004.
10. Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, et al: Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooporative Oncology Group experience. Gynecol Oncol 102: 285-291, 2006. (Pubitemid 44041640)
11. Utsunomiya H, Akahira J, Tanno S, Moriya T, Toyoshima M, Niikura H, et al: Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a muticenter trial. Int J Gynecol Cancer 16: 52-56, 2006.
12. Kobayashi H, Yamada Y, Kanayama S, Furukawa N, Noguchi T, Haruta S, et al: The role of hepatocyte nuclear factor-1beta in the pathogenesis of clear cell adenocarcinoma of the ovary. Int J Gynecol Cancer 19: 471-479, 2009.
13. Yamaguchi K, Mandai M, Oura T, Matsumura N, Hamanishi J, Bata T, et al: Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 29: 1741-1752, 2010.
14. Mamedava LK, Shneyvays V, Katz A and Shainberg A: Mechanism of glycogen supercompensation in rat skeletal muscle cultures. Mol Cell Biochem 250: 11-19, 2003. (Pubitemid 37045718)
15. Vigoda A, Mamedova LK, Shneyvays V, Katz A and Shainberg A: Glycogen metabolism in rat heart muscle cultures after hypoxia. Mol Cell Biochem 254: 311-318, 2003. (Pubitemid 37483767)
16. Savransky V, Nanayakkara A, Vivero A, Bevans S, Smith PL, Torbenson MS, et al: Chronic intermittent hypoxia predisposes to liver injury. Hepatology 45: 1007-1013, 2007. (Pubitemid 46631569)
17. Pescador N, Villar D, Cifuentes D, Garcia-Rocha M, Ortiz-Barahona A, Vazquez S, et al: Hypoxia promotes glycogen accumulation through hypoxia induced factor (HIF)-mediated induction of glycogen synthase 1. PLoS One 5: e9644, 2010.
18. Shen GM, Zhang FL, Liu XL and Zhang JW: Hypoxia-induced factor 1-mediated regulation of PPP1R3C promotes glycogen accumulation in human MCF-7 cells under hypoxia. FEBS Lett 584: 4366-4372, 2010.
19. Nicholas CD: Hypoxia, HIF1 and glucose metabolism in the solid tumor. Nat Rev Cancer 8: 705-713, 2008.
20. Wang GL, Jiang BH, Rue EA and Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by O2 tension. Proc Natl Acad Sci USA 92: 5510-5514, 1995.
21. Kaelin WG Jr and Ratciliffe PJ: Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 30: 393-402, 2008.
22. Semenza GL: HIF-1: upstream and downstream of cancer metabolism. Curr Opin Dev 20: 51-56, 2010.
23. Semenza GL: Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29: 625-634, 2010.
24. Yamamoto S, Tsuda H, Takano K, Iwaya K, Tamai S and Matsubara O: PIK3CA mutation is an early event in the development endometriosis-associated ovarian clear cell adenocarcinoma. J Pathol 225: 189-194, 2011.
25. Tsuchiya A, Sakamoto M, Yasuda J, ChumaM, Ohta T, Ohki M, et al: Expression profiling in ovarian clear cell carcinoma: identification of hepatocyto nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 163: 2503-2512, 2003. (Pubitemid 37466491)
26. Nakashima R, Enomoto T, Fujita M, Yoshino K, Wada H, Kondo K, et al: The von-Hippel-Lindau (VHL) tumor suppressor gene is not mutated in sporadic ovarian carcinoma. Oncol Rep 3: 887-890, 1996. (Pubitemid 26323746)
27. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7: 85-90, 1994. (Pubitemid 24232386)
28. Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, Zaridze D, et al: Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 14: 4726-4734, 2008.
29. Shuin T, Kondo K, Torigoe S, Kishida T, Kubota Y, Hosaka M, et al: Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 54: 2852-2855, 1994.
30. Duan DR, Pause A, Burgess WH, Aso T, Chen DY, Garrett KP, et al: Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269: 1402-1406, 1995.
31. Pause A, Lee S, Worrell RA, Chen DY, Burgess WH, Linehan WM, et al: The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci USA 94: 2156-2161, 1997. (Pubitemid 27136844)
32. Kibel A, Iliopoulos O, DeCaprio JA and Kaelin WG Jr: Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269: 1444-1446, 1995.
33. Berra E, Benizri E, Ginouvès A, Volmat V, Roux D and Pouyssèqur J: HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 22: 4082-4090, 2003. (Pubitemid 37021737)
34. Marsex JH, Stengel P, Doege K, Heikkinen P, Jokilehto T, Wagner T, et al: Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-proryl-4-hydroxylase. Biochem J 381: 761-767, 2004. (Pubitemid 39120486)
35. Pistollato F, Ramoazzo E, Abbadi S, Della Puppa A, Scienza R, D'Avella D, et al: Molecular mechanisms of HIF-1alpha modulation induced by oxygen tension and BMP2 in glioblastoma derived cells. PLoS One 4: e6206, 2009.
36. Barth S, Edlich F, Berchner-Pfannschmidt U, Gneuss S, Jahreis G, Hasgall PA, et al: Hypoxia-inducible factor prolyl-4-hydroxylase PHD2 protein abundance depends on integral membrane anchoring of FKBP38. J Biol Chem 284: 23046-23058, 2009.
37. Barth S, Nesper J, Hasgall PA, Wirthner R, Nytko KJ, Edlich F, et al: The peptidyl prolyl cis/trans isomerase FKBP38 determines hypoxia-inducible transcription factor prolyl-4-hydroxylase PHD2 protein stability. Mol Cell Biol 27: 3758-3768, 2007. (Pubitemid 46726183)
38. Luo W, Zhong J, Chang R, Hu H, Pandy A and Semenza GL: Hsp70 and CHIP selectively mediate ubiquition and degradation of hypoxia-inducible factor (HIF)-1alpha but Not HIF-2alpha. J Biol Chem 285: 3651-3663, 2010.
39. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F and Neckers LM: Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradation pathway. J Biol Chem 277: 29936-29944, 2002.
40. Embi N, Rylatt DB and Cohen P: Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 107: 519-527, 1980.
41. Luo J: Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett 273: 194-200, 2009.
42. Newqard CB, Brady MJ, O'Doherty RM and Saltiel AR: Organizing glucose disposal: emerging roles of glycogen targeting subunits of protein phosphatase-1. Diabetes 49: 1967-1977, 2000.
43. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al: High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554, 2004. (Pubitemid 38541907)
44. Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signaling controls tumour cell growth. Nature 441: 424-430, 2006. (Pubitemid 44050136)
45. Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, et al: Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 174: 1597-1601, 2009.
46. Jones S, Wang TL, Shih leM, Mao TL, Nakayama K, Roden R, et al: Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330: 228-231, 2010.
47. Kang S, Bader AG and Vogt PK: Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 102: 802-807, 2005. (Pubitemid 40282746)
48. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T and Vogt PK: Phosphatidyinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 12: 363-369, 2001. (Pubitemid 32685637)
49. Martinive P, Defresne F, Quaghebeur E, Daneau G, Crokart N, Grégoire V, et al: Impact of cyclen hypoxia on HIF-1alpha regulation in endothelial cell - new insights for anti-tumor treatments. FEBS J 276: 509-518, 2009.
50. Mottet D, Dumont V, Deccache Y, Demazy C, Ninane N, Rase M, et al: Regulation of hypoxia-inducible factor-1alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta pathway in HepG2 cells. J Biol Chem 278: 31277-31285, 2003. (Pubitemid 36994645)
51. An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV and Neckers LM: Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 392: 405-408, 1998.
52. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M and Hung MC: Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 6: 931-940, 2004. (Pubitemid 39359846)
53. Pruksakom D, Lirdprapamonqkol K, Chokchaichamnankit D, Subhasitanont P, Chiablaem K, Svasti J, et al: Metabolic alteration of HepG2 in scaffold-based 3-D culture: proteomic approach. Proteomics 10: 3896-3904, 2010.
54. Fischbach C, Chen R, Matsumoto T, Schmelzle T, Brugge JS, Polverini PJ, et al: Engineering tumors with 3D scaffolds. Nat Methods 4: 855-860, 2007. (Pubitemid 350055585)
55. Friedrich J, Seidel C, Ebner R and Kunz-Schuqhart LA: Spheroid-based drug screen: considerations and practical approach. Nat Protoc 4: 309-324, 2009.
56. Matsushima H, Shibata S, Asakura T, Matsuura T, Maehashi H, Ishii Y, Eda H, Aoki K, Iida Y, Morikawa T and Ohkawa K: Three-dimensional culture promotes reconstitution of the tumor-specific hypoxic microenvironment under TGFβ stimulation. Int J Oncol 39: 1327-1336, 2011.
57. Comeford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC and Colqan SP: Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62: 3387-3394, 2002. (Pubitemid 34651384)
58. Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58, 2002. (Pubitemid 37328807)
59. Hurley LH: DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer 2: 188-200, 2002.
60. Lee K, Qisn DZ, Rey S, Wei H, Liu JO and Semnza GL: Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci USA 406: 2353-2358, 2009.
61. Yamazaki Y, Hasebe Y, Egawa K, Nose K, Kunimoto S and Ikeda D: Anthracyclines, small-molecule inhibitors of hypoxia-inducible factor-1 alpha activation. Biol Pharm Bull 29: 1999-2003, 2006. (Pubitemid 44510798)
62. Tsuruo T, Kawabata H, Nagumo N, Iida H, Kitatani Y, Tsukagoshi S and Sakurai Y: Potentiation of antitumor agents by calcium channel blockers with special reference to cross-resistance patterns. Cancer Chemother Pharmacol 15: 16-19, 1985. (Pubitemid 15055610)
63. Dong J, Naito M, Tatsutaa T, Seimiya H, Johdo O and Tsuruo T: Difference between the resistance mechanism of aclacinomycin- and adriamycin-resistant P388 cell lines. Oncol Res 7: 245-252, 1995.
64. Tsuruo T, Iida-Saito H, Kawabata H, Oh-hara T, Hamada H and Utakoji T: Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones. Jpn J Cancer Res 77: 682-692, 1986. (Pubitemid 16072385)